Skip to main content
  • Contact Us
  • Vantage logo Sign Up
  • Subscriber Sign In
Evaluate Logo

navigation

  • What We Do
    • Commercial Intelligence
    • Products
      • Evaluate Pharma
      • Evaluate Omnium
      • Evaluate Medtech
      • Evaluate Epi
      • Japan Drug Forecasts
      • Europe Drug Forecasts
    • Pharma Consulting & Analytics
      • Pharma Consulting & Analytics
      • Data Feeds
    • Evaluate Vantage
      • News
      • Analysis
      • Policy & Pricing
      • Insights
      • Events
      • Medtech
      • Therapy Areas
      • Editorial Team
      • About Evaluate Vantage
    • Evaluate for Biotech
  • How We Can Help You
    • Pharma and Biotech
    • Financial Services
    • Management Consultancies
    • Service Providers
    • Customer Testimonials
  • Thought Leadership
    • Multimedia
    • Blog
  • About Us
    • Press Releases
    • Media Coverage
    • Executive Team
    • Vision & History
  • Contact Us
  • Sign Up for Evaluate Vantage
  • Talent
  • Subscriber Sign In

 

Vantage logo

Vantage

  • Covid-19
    • Covid-19 Coverage
    • Evaluate Vantage COVID-19 Report
  • News
    • Snippets
    • Deals
    • Trial results
    • Patents and litigation
    • Corporate strategy
  • Analysis
    • Interviews
    • Spotlight
    • Vantage points
    • Vantage views
  • Insights
    • M&A
    • IPO
    • NME approvals
    • Quarterly shareprice performance
    • Venture financing
    • Vantage data points
    • Other data
  • Events
    • Company events
    • Conferences
    • Upcoming events
  • Medtech
  • Therapy Areas
  • About
    • Editorial team

Breadcrumb

  1. Home
  2. Vantage
  3. Pharmaceutical Companies
  4. Foundation Medicine

Evaluate

Thumbnail
October 27, 2020

Exact chases its dream with $1.7bn Thrive deal

Setting its sights on the screening setting, Exact aims to be a major liquid biopsy player.

Thumbnail
September 16, 2020

With its liquid biopsy approval, Foundation Medicine takes on Guardant

The first pan-cancer approval might have gone to Guardant, but Roche’s subsidiary’s blood test appears to be able to find more markers.

Article image
Vantage logo
December 13, 2019

SABCS 2019 – Foundation's liquid biopsy helps predict triple-negative prognosis

Article image
Vantage logo
November 27, 2019

Veracyte’s nasal lung cancer test results raise questions

Amid the sea of lung cancer blood test developers, one company has nosed out a different approach.

Article image
Vantage logo
September 30, 2019

Esmo 2019 – Foundation eyes liquid biopsy rule change

New data could change liquid biopsy guidelines and boost sales, though regulatory approval would not be a bad idea.

Article image
Vantage logo
May 30, 2019

Thrive emerges with cash, a cancer blood test, and a plan

A new player has entered the liquid biopsy game.

Article image
Vantage logo
April 03, 2019

AACR 2019 – Foundation Medicine sets the scene for liquid biopsy approval

A study of a liquid biopsy and another looking at tumour mutational burden testing give early indications of Foundation’s approval strategy.

Article image
Vantage logo
January 24, 2019

Bristol makes investors squirm a little more

The latest setback to Bristol-Myers Squibb’s first-line lung cancer plan sees it pull its US filing for Opdivo plus Yervoy.

Article image
Vantage logo
December 13, 2018

Esmo-IO 2018 – Astrazeneca plays its tumour mutation burden card

Full results of the Mystic study present a controversial path forward for Imfinzi, and set the stage for the upcoming Neptune trial to be overhauled.

Article image
Vantage logo
July 05, 2018

Fireworks among the small and mid-cap device makers

Smaller medtechs saw impressive share price growth in 2018, but not quite as good as the year before.

Article image
Vantage logo
June 19, 2018

Roche hopes to lay a Foundation for growth

Cracking the cancer code.

  • Load More
Vantage logo
Independent, data-driven daily news and analysis on pharma, biotech and medtech.
Sign up

Latest Reports

May 15, 2023

Pharma’s Biggest Spenders 2022 Infographic

May 03, 2023

Gene Editing: Overhyped or Unstoppable Tide?

View more...

Editor's Picks

Vantage logo
May 16, 2023

Heightened US antitrust fears rattle biopharma

Vantage logo
May 11, 2023

2023’s biggest launches: the story so far

Vantage logo
May 17, 2023

Viking’s Voyage is not over yet

Vantage logo
May 09, 2023

Gene editing: overhyped or unstoppable tide?

Vantage logo
May 16, 2023

A slow (and low) year for FDA approvals

Open modal

Evaluate Logo

Evaluate HQ
44-(0)20-7377-0800

Evaluate Americas
+1-617-573-9450

Evaluate APAC
+81-80-1164-4754

Footer menu

  • Terms and conditions
  • Privacy Policies
  • Cookie Policy
  • Modern Slavery Statement

© Copyright 2023 Evaluate Ltd.

Sign up